BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 32520594)

  • 1. Fast-Acting Insulin Aspart Use with the MiniMed
    Hsu L; Buckingham B; Basina M; Ekhlaspour L; von Eyben R; Wang J; Lal RA
    Diabetes Technol Ther; 2021 Jan; 23(1):1-7. PubMed ID: 32520594
    [No Abstract]   [Full Text] [Related]  

  • 2. Fast-acting insulin aspart (Fiasp®) improves glycemic outcomes when used with MiniMed
    Grosman B; Wu D; Parikh N; Roy A; Voskanyan G; Kurtz N; Sturis J; Cohen O; Ekelund M; Vigersky R
    Comput Methods Programs Biomed; 2021 Jun; 205():106087. PubMed ID: 33873075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fast Acting Insulin Aspart Compared with Insulin Aspart in the Medtronic 670G Hybrid Closed Loop System in Type 1 Diabetes: An Open Label Crossover Study.
    Ozer K; Cooper AM; Ahn LP; Waggonner CR; Blevins TC
    Diabetes Technol Ther; 2021 Apr; 23(4):286-292. PubMed ID: 33090016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparable Glucose Control with Fast-Acting Insulin Aspart Versus Insulin Aspart Using a Second-Generation Hybrid Closed-Loop System During Exercise.
    Morrison D; Zaharieva DP; Lee MH; Paldus B; Vogrin S; Grosman B; Roy A; Kurtz N; O'Neal DN
    Diabetes Technol Ther; 2022 Feb; 24(2):93-101. PubMed ID: 34524022
    [No Abstract]   [Full Text] [Related]  

  • 5. Retrospective Analysis of 3-Month Real-World Glucose Data After the MiniMed 670G System Commercial Launch.
    Stone MP; Agrawal P; Chen X; Liu M; Shin J; Cordero TL; Kaufman FR
    Diabetes Technol Ther; 2018 Oct; 20(10):689-692. PubMed ID: 30160523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hybrid closed-loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: A double-blind, multicentre, multinational, randomized, crossover study.
    Boughton CK; Hartnell S; Thabit H; Poettler T; Herzig D; Wilinska ME; Ashcroft NL; Sibayan J; Cohen N; Calhoun P; Bally L; Mader JK; Evans M; Leelarathna L; Hovorka R
    Diabetes Obes Metab; 2021 Jun; 23(6):1389-1396. PubMed ID: 33606901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A fully artificial pancreas versus a hybrid artificial pancreas for type 1 diabetes: a single-centre, open-label, randomised controlled, crossover, non-inferiority trial.
    Tsoukas MA; Majdpour D; Yale JF; Fathi AE; Garfield N; Rutkowski J; Rene J; Legault L; Haidar A
    Lancet Digit Health; 2021 Nov; 3(11):e723-e732. PubMed ID: 34580055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycemic outcomes of children 2-6 years of age with type 1 diabetes during the pediatric MiniMed™ 670G system trial.
    Forlenza GP; Ekhlaspour L; DiMeglio LA; Fox LA; Rodriguez H; Shulman DI; Kaiserman KB; Liljenquist DR; Shin J; Lee SW; Buckingham BA
    Pediatr Diabetes; 2022 May; 23(3):324-329. PubMed ID: 35001477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, metabolic and psychological outcomes of Medtronic MiniMed 670G in children, adolescents and young adults: a systematic review.
    Mameli C; Smylie GM; Galati A; Rapone B; Cardona-Hernandez R; Zuccotti G; Delvecchio M
    Eur J Pediatr; 2023 May; 182(5):1949-1963. PubMed ID: 36809498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial.
    Bergenstal RM; Nimri R; Beck RW; Criego A; Laffel L; Schatz D; Battelino T; Danne T; Weinzimer SA; Sibayan J; Johnson ML; Bailey RJ; Calhoun P; Carlson A; Isganaitis E; Bello R; Albanese-O'Neill A; Dovc K; Biester T; Weyman K; Hood K; Phillip M;
    Lancet; 2021 Jan; 397(10270):208-219. PubMed ID: 33453783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Multicenter Randomized Trial Evaluating Fast-Acting Insulin Aspart in the Bionic Pancreas in Adults with Type 1 Diabetes.
    Beck RW; Russell SJ; Damiano ER; El-Khatib FH; Ruedy KJ; Balliro C; Li Z; Calhoun P
    Diabetes Technol Ther; 2022 Oct; 24(10):681-696. PubMed ID: 36173235
    [No Abstract]   [Full Text] [Related]  

  • 12. Optimizing Hybrid Closed-Loop Therapy in Adolescents and Emerging Adults Using the MiniMed 670G System.
    Messer LH; Forlenza GP; Sherr JL; Wadwa RP; Buckingham BA; Weinzimer SA; Maahs DM; Slover RH
    Diabetes Care; 2018 Apr; 41(4):789-796. PubMed ID: 29444895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety Evaluation of the MiniMed 670G System in Children 7-13 Years of Age with Type 1 Diabetes.
    Forlenza GP; Pinhas-Hamiel O; Liljenquist DR; Shulman DI; Bailey TS; Bode BW; Wood MA; Buckingham BA; Kaiserman KB; Shin J; Huang S; Lee SW; Kaufman FR
    Diabetes Technol Ther; 2019 Jan; 21(1):11-19. PubMed ID: 30585770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultrarapid Lispro Demonstrates Similar Time in Target Range to Lispro with a Hybrid Closed-Loop System.
    Bode B; Carlson A; Liu R; Hardy T; Bergenstal R; Boyd J; Morrett S; Ignaut D
    Diabetes Technol Ther; 2021 Dec; 23(12):828-836. PubMed ID: 34270335
    [No Abstract]   [Full Text] [Related]  

  • 15. Feasibility Study of a Hybrid Closed-Loop System with Automated Insulin Correction Boluses.
    Nimri R; Grosman B; Roy A; Nir J; Fisch Shvalb N; Kurtz N; Loewenthal N; Gillon-Keren M; Muller I; Atlas E; Phillip M
    Diabetes Technol Ther; 2021 Apr; 23(4):268-276. PubMed ID: 33185480
    [No Abstract]   [Full Text] [Related]  

  • 16. A Comparison of Postprandial Glucose Control in the Medtronic Advanced Hybrid Closed-Loop System Versus 670G.
    Weinzimer SA; Bailey RJ; Bergenstal RM; Nimri R; Beck RW; Schatz D; Ambler-Osborn L; Schweiger DS; von dem Berge T; Sibayan J; Johnson ML; Calhoun P; Phillip M;
    Diabetes Technol Ther; 2022 Aug; 24(8):573-582. PubMed ID: 35363054
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes.
    Jendle J; Pöhlmann J; de Portu S; Smith-Palmer J; Roze S
    Diabetes Technol Ther; 2019 Mar; 21(3):110-118. PubMed ID: 30785311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world performance of the MiniMed™ 670G system in Europe.
    Da Silva J; Bosi E; Jendle J; Arrieta A; Castaneda J; Grossman B; Cordero TL; Shin J; Cohen O
    Diabetes Obes Metab; 2021 Aug; 23(8):1942-1949. PubMed ID: 33961340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion.
    Bode BW; Johnson JA; Hyveled L; Tamer SC; Demissie M
    Diabetes Technol Ther; 2017 Jan; 19(1):25-33. PubMed ID: 28055230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Glycemic Outcomes During the MiniMed
    Pihoker C; Shulman DI; Forlenza GP; Kaiserman KB; Sherr JL; Thrasher JR; Buckingham BA; Kipnes MS; Bode BW; Carlson AL; Lee SW; Latif K; Liljenquist DR; Slover RH; Dai Z; Niu F; Shin J; Jonkers RAM; Roy A; Grosman B; Vella M; Cordero TL; McVean J; Rhinehart AS; Vigersky RA;
    Diabetes Technol Ther; 2023 Nov; 25(11):755-764. PubMed ID: 37782145
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.